Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.45 |
| ▸ | APP | P05067 | 4/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1392367 | 0.86 | ESR1 (0.44) | ESR1CRHR1SYKKCNH3IDH2 | |
| SCHEMBL1391765 | 0.81 | TDP1 (0.43) | ESR1SYKKCNH3 | |
| SCHEMBL1391497 | 0.78 | KCNH3 (0.49) | ESR1SYKKCNH3 | |
| SCHEMBL1392426 | 0.77 | MEN1 (0.45) | ESR1CRHR1APPSYKKCNH3 | |
| SCHEMBL20511113 | 0.76 | CA12 (0.54) | CRHR1APPCA9PDE2A | |
| SCHEMBL1392077 | 0.75 | ESR1 (0.41) | ESR1SYKKCNH3 | |
| SCHEMBL1391414 | 0.73 | APP (0.78) | APPKCNH3IDH2 | |
| SCHEMBL22803975 | 0.72 | ESR1 (0.61) | ESR1SYK | |
| SCHEMBL1392057 | 0.72 | KCNH3 (0.46) | SYKKCNH3CA9 | |
| SCHEMBL27935508 | 0.71 | NR1I2 (0.56) | APPKCNH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | HAVCR2, ZC3HAV1, MAVS | ESR1 4654/4885CRHR1 3723/4885APP 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.